IBS-C 치료를 위한 테나파노르의 안전성 및 효능 평가 연구
12~18세 미만 소아 환자의 변비가 있는 과민성 대장 증후군(IBS-C) 치료를 위한 테나파노르의 안전성과 효능을 평가하기 위한 12주, 무작위, 이중맹검, 위약 대조, 3상 연구
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and <18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This study consists of 2-week screening period followed by 12 week randomized treatment period (RTP) and a 2-week treatment-free Follow-Up period (only for patients who will not enter the 40-week Long Term Safety Extension Study [TEN-01-306]). At the beginning of the 2-week Screening period, patients who provide written assent will be fully assessed for eligibility into the study and will be asked to self-report daily information about the status of their IBS symptoms via an electronic diary (eDiary) device. Patient compliance with the eDiary will be monitored actively by the site staff and will be reviewed to determine eligibility at the end of screening. Eligible patients will be randomized to receive one of the study medications: tenapanor 25 mg BID, tenapanor 50 mg BID, or placebo.
During the 12-week double-blind RTP, patients will continue recording daily assessments via the eDiary system as instructed and compliance with eDiary entries will be monitored on an ongoing basis. Patients will return for study visit every two or four weeks (Visits 3-6) and will undergo safety assessments at these visits.
Patients who do not enter the 40-week Long Term Safety Extension Study [TEN-01-306] including those who complete the RTP but do not enter study TEN-01-306 and those who prematurely discontinue from the RTP, a Follow-Up Visit will be scheduled approximately 2 weeks after the completion of the RTP (Visit 6) or the Early Termination Visit at which safety assessments will be performed
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 3단계
연락처 및 위치
연구 장소
-
-
Alabama
-
Foley, Alabama, 미국, 36535
- G & L Research, LLC
-
-
Arizona
-
Tucson, Arizona, 미국, 85745
- Eclipse Clinical Research
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72205
- Applied Research Center of Arkansas
-
-
California
-
Anaheim, California, 미국, 92805
- Advanced Research Center, Inc.
-
-
Connecticut
-
Hartford, Connecticut, 미국, 06106
- Connecticut Children's Medical Center
-
-
Florida
-
Doral, Florida, 미국, 33166
- Prohealth Research Center
-
Kissimmee, Florida, 미국, 34741
- I.H.S. Health, LLC
-
Miami, Florida, 미국, 33165
- Valencia Medical and Research Center
-
Miami, Florida, 미국, 33155
- Waterway Research & Associates Corp
-
Orlando, Florida, 미국, 32806
- Orlando Health, Inc.- APH Center for Digestive Health and Nutrition
-
South Miami, Florida, 미국, 33143
- Florida Pharmaceutical Research and Associates, Inc.
-
-
Georgia
-
Stockbridge, Georgia, 미국, 30281
- Clinical Research Institute
-
-
Illinois
-
Peoria, Illinois, 미국, 61637
- OSF Saint Francis Medical Center
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- Riley Children's Health IUH
-
-
Maine
-
Portland, Maine, 미국, 04102
- Maine Health
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- Boston Children's Hospital
-
-
Minnesota
-
Mankato, Minnesota, 미국, 56001
- Mankato Clinic/ Javara Research Ltd
-
-
Nebraska
-
Boys Town, Nebraska, 미국, 68010
- Boys Town National Research Hospital
-
-
New Jersey
-
Irvington, New Jersey, 미국, 07111
- Med Clinical Research Partners, LLC
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87131
- University of New Mexico Health Sciences Center
-
-
New York
-
Brooklyn, New York, 미국, 11203
- SUNY Downstate Medical Center
-
Rochester, New York, 미국, 14642
- University of Rochester
-
The Bronx, New York, 미국, 10467
- Advantage Clinical Trials
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28203
- Atrium Health
-
Durham, North Carolina, 미국, 27705
- Duke University School of Medicine
-
Wilmington, North Carolina, 미국, 28401
- Wilmington Health
-
-
Pennsylvania
-
Scottdale, Pennsylvania, 미국, 15683
- Frontier Clinical Research, LLC
-
Smithfield, Pennsylvania, 미국, 15478
- Frontier Clinical Research, LLC
-
-
South Carolina
-
Greenville, South Carolina, 미국, 29615
- Prisma Health Children's Hospital
-
-
Texas
-
Abilene, Texas, 미국, 79606
- Advance Clinical Trial PLLC
-
El Paso, Texas, 미국, 79902
- Maspons Pediatric Gastro
-
El Paso, Texas, 미국, 79902
- Proactive El Paso, LLC
-
Harlingen, Texas, 미국, 78550
- Texas Digestive Specialists
-
Plano, Texas, 미국, 75093
- AIM Trials, LLC
-
San Antonio, Texas, 미국, 78215
- Sun Research Institute
-
Sugar Land, Texas, 미국, 77479
- Pioneer Research Solutions Inc
-
Waxahachie, Texas, 미국, 75165
- ClinPoint Trials
-
-
West Virginia
-
Huntington, West Virginia, 미국, 25701
- University Physicians and Surgeons, Inc.
-
Kingwood, West Virginia, 미국, 26537
- Frontier Clinical Research
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- ≥12 and <18 years old
- Patient weighs ≥18 kg at the time the patient provides written assent
- Females of child-bearing potential must have negative pregnancy test at Visit 1 (serum) and Visit 2 (urine) and confirm the use of appropriate contraception (including abstinence).
- Patient meets the Rome IV criteria for child/adolescent diagnosis of IBS-C
- Patient is willing to discontinue any laxatives used in favor of the protocol-permitted rescue medicine (which will only be allowed after 72 hours with no bowel movement)
- Patient meets the entry criteria assessed during the 2-week Screening period.
- Ability of both the patient and parent/guardian/LAR to communicate with the Investigator and to comply with the requirements of the entire study, including an understanding of the assessments in the eDiary and how to use the eDiary device
- Patient must provide written assent and the parent/guardian/LAR must provide written informed consent before the initiation of any study-specific procedures
Exclusion Criteria:
-
Functional diarrhea as defined by Rome IV child/adolescent criteria
-
IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Rome IV child/adolescent criteria
-
History of non-retentive fecal incontinence.
-
Required manual disimpaction any time prior to randomization (after consent);
-
Has both unexplained and clinically significant alarm symptoms (lower gastrointestinal [GI] bleeding [rectal bleeding or heme-positive stool], iron-deficiency anemia, or any unexplained anemia, or weight loss) and systemic signs of infection or colitis, or any neoplastic process
-
Patient has any of the following conditions:
- Celiac disease, or positive serological test for celiac disease
- Cystic fibrosis
- Hypothyroidism that is untreated or treated with thyroid hormone
- Down's syndrome or any other chromosomal disorder
- Active anal fissure
- Anatomic malformations (eg, imperforate anus)
- Intestinal nerve or muscle disorders (eg, Hirschprung disease)
- Neuropathic conditions (eg, spinal cord abnormalities)
- Lead toxicity, hypercalcemia
- Neurodevelopmental disabilities producing a cognitive delay that precludes comprehension and completion of the daily eDiary (Electronic handheld device)
- Inflammatory bowel disease
- Childhood functional abdominal pain syndrome
- Childhood functional abdominal pain;
- Poorly treated or poorly controlled psychiatric disorders that might influence his or her ability to participate in the study;
- Lactose intolerance that is associated with abdominal pain or discomfort
- History of cancer other than treated basal cell carcinoma of the skin; (Note: Patients with a history of cancer are allowed provided that the malignancy has been in a complete remission for at least 5 years before the Randomization Visit.)
- History of diabetic neuropathy.
-
Use of medications that are known to affect stool consistency (Prohibited Medications), including fiber supplements, anti-diarrheals, cathartics, antacids, opiates, prokinetic drugs, laxatives, enemas, antibiotics during the Screening period; unless specified as rescue medication, and used accordingly as directed by the Investigator.
-
Patient has had surgery that meets any of the following criteria:
- Bariatric surgery for treatment of obesity, or surgery to remove a segment of the GI tract at any time before the Screening Visit;
- Surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months before the Screening Visit;
- An appendectomy or cholecystectomy during the 60 days before the Screening Visit;
- Other major surgery during the 30 days before the Screening Visit
-
History of alcohol or substance abuse
-
Participation in other clinical trials within 1 month prior to Screening
-
Patient and/or parent/guardian/LAR is involved in the conduct and/or administration of this trial as an investigator, sub-investigator, trial coordinator, or other staff member, or the patient is a first-degree family member, significant other, or relative residing with one of the above persons involved in the trial
-
If, in the opinion of the Investigator, the patient is unable or unwilling to fulfill the requirements of the protocol or has a condition, which would render the results uninterpretable
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Tenpanor 50 mg BID
Patients will be randomized to receive 50 mg tenapanor twice daily |
Participants will receive tenapanor 50 mg BID (total of 100 mg daily) |
|
실험적: Tenpanor 25 mg BID
Patients will be randomized to receive 25 mg tenapanor twice daily |
Participants will receive tenapanor 25 mg BID (total of 50 mg daily) |
|
위약 비교기: Placebo Comparator
Patients will be randomized to receive matching placebo twice daily |
Participants will be randomized to receive matching placebo |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
6/12-week APS (abdominal pain and SBM) +2 response
기간: 12 weeks
|
6/12-week APS (abdominal pain and SBM (spontaneous bowel movement)) +2 response, defined as achieving the weekly APS +2 response criteria (i.e., achieving both weekly SBM +2 response and weekly abdominal pain response during the same week) for ≥6 out of the 12 weeks of the RTP.
|
12 weeks
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
6/12-week SBM +2 response
기간: 12 weeks
|
6/12-week SBM +2 response: defined as achieving the weekly SBM +2 response for ≥6 out of the 12 weeks of the RTP |
12 weeks
|
|
6/12-week abdominal pain response
기간: 12 weeks
|
6/12-week abdominal pain response: defined as achieving the weekly abdominal pain response for ≥6 out of the 12 weeks of the RTP |
12 weeks
|
|
Change from baseline in average weekly SBM frequency
기간: 12 weeks
|
Change from baseline in average weekly SBM frequency |
12 weeks
|
|
Change from baseline in average weekly stool consistency score
기간: 12 weeks
|
Change from baseline in average weekly stool consistency score |
12 weeks
|
|
Change from baseline in average weekly abdominal pain score
기간: 12 weeks
|
Change from baseline in average weekly abdominal pain score |
12 weeks
|
|
Overall use of rescue medication
기간: 12 weeks
|
Overall use of rescue medication |
12 weeks
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Jocelyn Tabora, Ardelyx
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- TEN-01-304
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .